Bile Duct Carcinoma clinical trials
12 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
- Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
- A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease
- EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
- Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy
- Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
- Integrated Cancer Repository for Cancer Research
- Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
- Resilience and Equity in Aging, Cancer, and Health (REACH)
- Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies
- TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Bile Duct Carcinoma” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.